glp-1 dementia study drugs failed to slow Alzheimer's in two big clinical trials Comparative dementia risk with GLP1

And theyve become household names in ways that very few medications ever do

Tracking biomarkers across these systems enables better care 85%+ Muscle mass preserved With guidance, patients preserve lean muscle through targeted protein and strength protocols Most GLP-1 programs fall short Without clinical support Higher risk of losing lean tissue Muscle loss Derail treatment adherence Side effects Weight loss without metabolic health No metabolic tracking Most quit within 6 months Early discontinuation Multi-system intervention Success measured across the body Clinician-led care with ongoing oversight Dosing, tolerance, and response actively managed Decisions guided by biological feedback Biomarkers and symptoms used to protect long-term health Long-term healthspan Designed to support aging, resilience, and metabolic health Clinician-guided GLP-1 treatment Your clinician reviews your medical history and goals to determine eligibility and guide the right treatment choice, including injectable or oral options

This strikes the best balance between injection volume and measurement precision

Understanding the relationship between semaglutide units and milligrams helps you maintain accurate dosing